When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...
In the sleepy suburbs of Bremerton, Washington, US, a Hollywood story became a real-life mystery that still haunts Tinseltown today. On January 5, 2006, 18-year-old Joe Pichler went missing without a ...
In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...
After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...
Back in 2018, a Tampa woman named Gabrielle Hartley faced every dog parent’s worst nightmare. Her beloved Husky, Luca, was stolen right from her home. Yet through all the heartbreak, she never lost ...
Richard Aldrich, a 98-year-old WWII Navy veteran, will be rooting for Navy over Notre Dame. Aldrich enlisted in the Navy at 17 in 1945 and served for over a year in the Pacific. He is one of an ...
After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...
August 15, 2025 Add as a preferred source on Google Add as a preferred source on Google Apple gets some flack from the tech community for stealing features from Android, but the truth is, the theft ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.41187 EPS, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback